About Us 

Founded in 1987 as a cutting-edge drug discovery biotech in La Jolla, California, Ligand Pharmaceuticals has built a rich 24-year heritage of drug discovery and development innovation. Ligand has used its drug development expertise to produce over 40 clinical candidates, 22 INDs, and 5 approved drugs. That's a level of productivity that ranks near the top of the biotech industry.

Today, Ligand is a specialty biotech company based on a business model of developing or acquiring technology and royalty revenue generating assets that are coupled to a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of technologies and assets across numerous therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to spread their risk while investing in the increasingly complicated and unpredictable pharmaceutical industry.

Ligand recognized the important role of the drug reformulation segment in the pharmaceutical industry and added Captisol® to its technology portfolio. Captisol is a powerful formulation technology that has enabled five FDA approved products, including Pfizer's VFEND® IV and Baxter International's Nexterone ®. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate significant revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc. and The Medicines Company.